GB Sciences, Inc. (GBLX)

0.0065 -0.0003 (-4.41%) At close: 03:37PM EDT

GB Sciences, Inc.

9205 W. Russell Road
Suite 240
Las Vegas, NV 89148
United States
866-721-0297
https://www.gbsciences.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 3

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. John Claybron Poss	CEO, Interim CFO & Chairman	60k	N/A	1948
Dr. Andrea Small-Howard M.B.A., MBA, Ph.D.	Chairman of Scientific Advisory Board, Chief Science Officer, President & Director	138k	N/A	1969
Mr. Gary R. Henrie Esq.	Securities Counsel & Company Secretary	N/A	N/A	1954

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GB Sciences, Inc., a phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.

Corporate Governance

GB Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.